GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

Right now, Gilead Sciences is sporting a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that GILD likely has seen a ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

Dan Ashley , acclaimed journalist and ABC-7 San Francisco Bay Area News anchor, will serve as the emcee for World AIDS Day. Honored with a park bench in the National AIDS Memorial Grove for his ...

Dr. Reddy’s Laboratories RDY announced that it has launched a biosimilar of Coherus BioSciences’ CHRS Loqtorzi (toripalimab) ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

Inside the plan to address the issues of exploitation and inequality facing development consultants. Plus, ahead of World ...

The head of MI6 says British security will be "jeopardised" if Putin is allowed to succeed in Ukraine, as he warned the spy agency has already uncovered a Russian sabotage campaign in Europe.